Neogenomics Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Yeah. Great. Yeah, that was a great overview. I guess to start, Chris, to address the elephant in the room, why do you feel that now is the right time to step away from NeoGenomics?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : No, that's helpful. I have a couple here just on the '25 guide, and then we can open it up to questions. But your guidance in the long-range plan indicates 12% to 13% revenue growth annually. Can you just walk us through the key drivers there and the confidence that you can achieve those results?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Okay. Got you. That's a lot of helpful color. I guess maybe stepping back high level, NeoGenomics' financials have greatly improved since you guys took over in August 2022. Maybe what's the next phase of growth and transformation for the company that you see?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Okay. I'll open it up now to the audience. Anybody have any questions, we can run this mic around. Unidentified Analyst Thank you for sharing the very strong financial results. My question is about how big is the pharma-related services in NeoGenomics? And what's the position of NeoGenomics in the pharma-related services like the target discovery, biomarker discovery, or clinical trial? And what's your competition status with the current market leaders such as Farage Medicine or TSO 500 in NGS territory?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : And maybe, Jeff, you can talk about why we went through the transformation in pharma?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Anybody else have questions from the crowd? I have one on NGS here. In 3Q, you guys grew NGS by 35%. Can you just talk about that growth rate and the sustainability of the mix shift that you're seeing in NGS?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Do you want to talk about like how you guys are winning?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Yeah. That's helpful. Maybe one just on MRD. Can you walk us through any updates you can share on the development of RADAR 1.1 and just your MRD program in general?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Okay. Got it. That's helpful. Chris, you mentioned that the company has started to evaluate BD opportunities. What's your appetite for investing in M&A?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : I'll open it up to the audience again for any questions. Got one last question.

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : All right. I hear you. I got one maybe in closing just -- what do you think is the most underappreciated aspect of the NeoGenomics story?

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Do you guys have one or two on -- you can pick one each, if I didn't hit it. You've taken the three good ones. There you go. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 15, 2025 / 9:30PM, NEO.OQ - Neogenomics Inc at JPMorgan Healthcare Conference

Question: Casey Woodring - JPMorgan Securities LLC - Analyst : Yeah. We'll leave it there. Appreciate everybody for coming today. Thank you, NeoGenomics.